Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 16c

Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q4 EPS of ($0.20), $0.16 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $27.38 million versus the consensus estimate of $18.2 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
• InterCure reaches NIS 230M war damage settlement with Israel